These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

739 related articles for article (PubMed ID: 25755769)

  • 1. Histological and immunohistochemical markers for progression prediction in transurethrally resected high-grade non-muscle invasive bladder cancer.
    Kim K; Cho YM; Park BH; Lee JL; Ro JY; Go H; Shim JW
    Int J Clin Exp Pathol; 2015; 8(1):743-50. PubMed ID: 25755769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
    Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
    J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer.
    Passoni N; Gayed B; Kapur P; Sagalowsky AI; Shariat SF; Lotan Y
    Urol Oncol; 2016 Nov; 34(11):485.e7-485.e14. PubMed ID: 27637323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoprofile-based subgrouping of urothelial bladder carcinomas for survival prediction.
    Kim K; Sung CO; Park BH; Ku JY; Go H; Ro JY; Kim J; Cho YM
    Hum Pathol; 2015 Oct; 46(10):1464-70. PubMed ID: 26232864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue factor expression correlates with disease-specific survival in patients with node-negative muscle-invasive bladder cancer.
    Patry G; Hovington H; Larue H; Harel F; Fradet Y; Lacombe L
    Int J Cancer; 2008 Apr; 122(7):1592-7. PubMed ID: 18058798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
    Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
    Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation.
    May M; Helke C; Nitzke T; Vogler H; Hoschke B
    Urol Int; 2004; 72(2):103-11. PubMed ID: 14963349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphovascular invasion, ureteral reimplantation and prior history of urothelial carcinoma are associated with poor prognosis after partial cystectomy for muscle-invasive bladder cancer with negative pelvic lymph nodes.
    Ma B; Li H; Zhang C; Yang K; Qiao B; Zhang Z; Xu Y
    Eur J Surg Oncol; 2013 Oct; 39(10):1150-6. PubMed ID: 23721764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fatty acid synthase, Her2/neu, and E2F1 as prognostic markers of progression in non-muscle invasive bladder cancer.
    Abdelrahman AE; Rashed HE; Elkady E; Elsebai EA; El-Azony A; Matar I
    Ann Diagn Pathol; 2019 Apr; 39():42-52. PubMed ID: 30684846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EORTC progression score identifies patients at high risk of cancer-specific mortality after radical cystectomy for secondary muscle-invasive bladder cancer.
    May M; Burger M; Brookman-May S; Stief CG; Fritsche HM; Roigas J; Zacharias M; Bader M; Mandel P; Gilfrich C; Seitz M; Tilki D
    Clin Genitourin Cancer; 2014 Aug; 12(4):278-86. PubMed ID: 24331576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER-2 immunohistochemical expression as prognostic marker in high-grade T1 bladder cancer (T1G3).
    Bongiovanni L; Arena V; Vecchio FM; Racioppi M; Bassi P; Pierconti F
    Arch Ital Urol Androl; 2013 Jun; 85(2):73-7. PubMed ID: 23820653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of positive urine cytology on progression and cancer-specific mortality of non--muscle-invasive bladder cancer.
    Koga F; Kobayashi S; Fujii Y; Ishioka J; Yokoyama M; Nakanishi Y; Matsuoka Y; Numao N; Saito K; Masuda H; Kihara K
    Clin Genitourin Cancer; 2014 Jun; 12(3):e87-93. PubMed ID: 24169493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
    Słojewski M
    Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy.
    Lotan Y; Bagrodia A; Passoni N; Rachakonda V; Kapur P; Arriaga Y; Bolenz C; Margulis V; Raj GV; Sagalowsky AI; Shariat SF
    Eur Urol; 2013 Sep; 64(3):465-71. PubMed ID: 23571005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sphingosine-1-phosphate receptor 1 (S1PR1) expression in non-muscle invasive urothelial carcinoma: Association with poor clinical outcome and potential therapeutic target.
    Go H; Kim PJ; Jeon YK; Cho YM; Kim K; Park BH; Ku JY
    Eur J Cancer; 2015 Sep; 51(14):1937-45. PubMed ID: 26238015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitivity of initial biopsy or transurethral resection of bladder tumor(s) for detecting histological variants on radical cystectomy.
    Ge P; Wang ZC; Yu X; Lin J; He Q
    BMC Urol; 2015 May; 15():46. PubMed ID: 26025446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of the combined expression of tumor-associated trypsin inhibitor (TATI) and p53 in patients with bladder cancer undergoing radical cystectomy.
    Liu A; Xue Y; Liu F; Tan H; Xiong Q; Zeng S; Zhang Z; Gao X; Sun Y; Xu C
    Cancer Biomark; 2019; 26(3):281-289. PubMed ID: 31594208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma.
    Milojevic B; Djokic M; Sipetic-Grujicic S; Grozdic Milojevic I; Vuksanovic A; Nikic P; Vukovic I; Djordjevic D; Bumbasirevic U; Tulic C
    Urol Oncol; 2013 Nov; 31(8):1615-20. PubMed ID: 22521771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Muscle-invasive bladder cancer developing after nephroureterectomy for upper urinary tract urothelial carcinoma.
    Kim KH; You D; Jeong IG; Hong JH; Ahn H; Kim CS
    Urol Oncol; 2013 Nov; 31(8):1643-9. PubMed ID: 22591745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.